IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans.

"Conflicts of interest The authors disclose no conflicts."

"Funding This work was supported in part by the 10.13039/501100001659Deutsche Forschungsgemeinschaft (grant SFB841 to Samuel Huber, Nicola Gagliani, Ansgar W. Lohse, grant DFG TRR241 A03 to Andrey A. Kruglov and grant SFB1328 to Samuel Huber, Nicola Gagliani, and Andreas H. Guse), the 10.13039/501100000781European Research Council (starting grant 337251 to Samuel Huber), Ernst 10.13039/501100004038Jung-Stiftung Hamburg (to Samuel Huber), Stiftung Experimentelle Biomedizin (to Samuel Huber), and the 10.13039/100000011Howard Hughes Medical Institute (to Richard A. Flavell). Samuel Huber has an endowed Heisenberg-Professorship awarded by the 10.13039/501100001659Deutsche Forschungsgemeinschaft . All data necessary to understand and assess the conclusions of the article are available in the body of the article and in the Supplementary Materials . Il22- (VG1150) and Il22bp- (VG437) deficient mice are available from Regeneron under a material transfer agreement with the University Medical Center Hamburg-Eppendorf. Agonistic and Antagonistic lymphotoxin beta receptor antibodies were kindly provided by Biogen.inc under a material transfer agreement with the University Medical Center Hamburg-Eppendorf."